Septa Pharmaceuticals Reinforces Oncology Portfolio with CeeNU Acquisition from Bristol Myers Squibb

Septa Pharmaceuticals Expands Oncology Offerings through CeeNU Acquisition

Mississauga, ON - In a strategic move, Septa Pharmaceuticals Inc., recognized as a prominent player in the Canadian healthcare landscape, proudly announced on July 15, 2026, the successful acquisition of CeeNU® (Lomustine) from Bristol Myers Squibb. This vital acquisition, finalized on June 29, 2026, marks a significant milestone in Septa's continued growth and expansion, particularly within the specialty oncology segment.

CeeNU® (Lomustine), an effective alkylating agent, plays a crucial role in the treatment of specific brain tumors and Hodgkin’s lymphoma. By integrating this essential chemotherapy medication into its product offerings, Septa strengthens its commitment to providing effective treatment options for patients battling severe health conditions.

Septa Pharmaceuticals has emphasized its dedication to ensuring uninterrupted access for patients requiring CeeNU® across Canada. In response to the increasing demand for a stable and robust supply of essential medications, the company is prioritizing the continuous availability of this critical treatment amid the complexities of today’s healthcare environment.

Devinder K., President and CEO of Septa Pharmaceuticals, stated, "Our focus during this transition is firmly positioned on the patients and the healthcare professionals who care for them. We are collaborating closely with all relevant stakeholders, including regulatory bodies and supply chain partners, to facilitate a seamless integration of CeeNU® (Lomustine) into our portfolio. This acquisition underscores our mission to enhance health outcomes with high-quality, reliable pharmaceutical products."

As Septa Pharmaceuticals expands its diverse product pipeline, the company is exploring new strategic partnerships and licensing opportunities within the pharmaceutical sector. It welcomes collaborations with other pharmaceutical entities to out/in-license, launch, and commercialize high-impact therapies globally. By working together, these partnerships aim to ensure that crucial medications reach the markets where they are needed most.

About Septa Pharmaceuticals Inc.

Based in Ontario, Canada, Septa Pharmaceuticals is committed to the development, acquisition, and commercialization of specialized pharmaceuticals on a global scale. With a patient-first approach, the company strives to address critical gaps in the healthcare market by stabilizing the supply of essential medicines. Through targeted acquisitions and strategic partnerships, Septa is developing a robust product pipeline and managed access programs to meet the evolving needs of the medical community worldwide.

In summary, the acquisition of CeeNU® (Lomustine) signifies a pivotal step in Septa Pharmaceuticals' journey to enhance its oncology footprint and deliver vital therapeutic options to patients who need them. The strategic objectives set forth by the company reflect its unwavering dedication to patient care and commitment to fostering collaborations that promote healthcare advancements.